Sylvia Zhao

1.2k total citations
16 papers, 881 citations indexed

About

Sylvia Zhao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Sylvia Zhao has authored 16 papers receiving a total of 881 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Hepatology. Recurrent topics in Sylvia Zhao's work include Lung Cancer Treatments and Mutations (7 papers), Liver physiology and pathology (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Sylvia Zhao is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Liver physiology and pathology (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Sylvia Zhao collaborates with scholars based in China, Switzerland and United States. Sylvia Zhao's co-authors include Wu‐Chou Su, Mikhail Akimov, Fei Su, Kenneth Kolinsky, Raman Iyer, Zenaida Go, Kathryn Packman, Hong Yang, Gideon Bollag and Kathleen Schostack and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Sylvia Zhao

16 papers receiving 861 citations

Peers

Sylvia Zhao

ONCOL

PRM

PFM

HEPAT

Jessica Orf United States

Zhixing Guo China

Robin M.J.M. van Geel Netherlands

Haitian Quan China

Hendrik‐Tobias Arkenau United Kingdom

Julie C. Lougheed United States

Jean Cui United States

Yu-Chien Chou United States

Jingrong Jean Cui United States

Mitchell D. Nambu United States

Jessica Orf United States

Sylvia Zhao

545 ×1.1

507 ×1.2

ONCOL

437 ×1.3

PRM

205 ×1.3

PFM

243 ×1.8

HEPAT

Citations per year, relative to Sylvia Zhao Sylvia Zhao (= 1×) peers Jessica Orf

Countries citing papers authored by Sylvia Zhao

Since Specialization

Citations

This map shows the geographic impact of Sylvia Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvia Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvia Zhao more than expected).

Fields of papers citing papers by Sylvia Zhao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvia Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvia Zhao. The network helps show where Sylvia Zhao may publish in the future.

Co-authorship network of co-authors of Sylvia Zhao

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvia Zhao. A scholar is included among the top collaborators of Sylvia Zhao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvia Zhao. Sylvia Zhao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Huang, Zhijun, Yingying Wang, Guoping Yang, et al.. (2023). The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia. Journal of clinical lipidology. 17(3). 392–400. 22 indexed citations

Zang, Richard, Harvey Wong, Jan Mařı́k, et al.. (2022). Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) Evaluation. Journal of Medicinal Chemistry. 65(13). 8713–8734. 17 indexed citations

Delord, Jean‐Pierre, Guillem Argilés, Jérôme Fayette, et al.. (2020). A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. Investigational New Drugs. 38(6). 1774–1783. 17 indexed citations

Rajman, Iris, et al.. (2020). New paradigm for expediting drug development in Asia. Drug Discovery Today. 25(3). 491–496. 7 indexed citations

Glaenzel, Ulrike, Yi Jin, Kirsten Schroer, et al.. (2020). Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite. Drug Metabolism and Disposition. 48(10). 873–885. 31 indexed citations

Bent, Martin J. van den, Analía Azaro, Filip De Vos, et al.. (2019). A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. Journal of Neuro-Oncology. 146(1). 79–89. 36 indexed citations

Raab, Marc S., Sheeba K. Thomas, Enrique M. Ocio, et al.. (2019). The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. Leukemia. 33(12). 2924–2933. 52 indexed citations

Zhang, Jiang-Wei, Jing Dai, Qian Li, et al.. (2019). In Vitro Metabolism by Aldehyde Oxidase Leads to Poor Pharmacokinetic Profile in Rats for c-Met Inhibitor MET401. European Journal of Drug Metabolism and Pharmacokinetics. 44(5). 669–680. 1 indexed citations

Bang, Yung‐Jue, Wu‐Chou Su, Martin Schüler, et al.. (2019). Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts. Cancer Science. 111(2). 536–547. 50 indexed citations

10.

Wu, Yi‐Long, Li Zhang, Dong‐Wan Kim, et al.. (2018). Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 36(31). 3101–3109. 244 indexed citations

11.

Bent, Martin J. van den, Analía Azaro, Filip De Vos, et al.. (2017). ACTR-74. A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology. 19(suppl_6). vi16–vi17. 1 indexed citations

12.

Xia, Lei, Xin Hong, Yinghua Qu, et al.. (2015). Cytochrome P450 induction response in tethered spheroids as a three‐dimensional human hepatocyte in vitro model. Journal of Applied Toxicology. 36(2). 320–329. 13 indexed citations

13.

Zhao, Sylvia, Lingling Zhang, Xiaoyun Wu, et al.. (2014). 4β-Hydroxycholesterol as an Endogenous Biomarker of CYP3A Activity in Cynomolgus Monkeys. Drug Metabolism and Disposition. 42(5). 839–843. 9 indexed citations

14.

Bang, Yung‐Jue, Wu‐Chou Su, Do‐Hyun Nam, et al.. (2014). Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2520–2520. 41 indexed citations

15.

Wu, Yi‐Long, James Chih‐Hsin Yang, Dong‐Wan Kim, et al.. (2014). Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.. Journal of Clinical Oncology. 32(15_suppl). 8017–8017. 33 indexed citations

16.

Yang, Hong, Brian Higgins, Kenneth Kolinsky, et al.. (2010). RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models. Cancer Research. 70(13). 5518–5527. 307 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact